Drug Type Monoclonal antibody |
Synonyms Clazakizumab (USAN/INN), ALD 518, ALD-518 + [6] |
Target |
Action inhibitors |
Mechanism IL-6 inhibitors(Interleukin-6 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhasePhase 2/3 |
First Approval Date- |
RegulationOrphan Drug (United States) |


| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D10312 | Clazakizumab | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Kidney Failure, Chronic | Phase 3 | United States | 27 Apr 2024 | |
| Kidney Failure, Chronic | Phase 3 | China | 27 Apr 2024 | |
| Kidney Failure, Chronic | Phase 3 | Japan | 27 Apr 2024 | |
| Kidney Failure, Chronic | Phase 3 | Argentina | 27 Apr 2024 | |
| Kidney Failure, Chronic | Phase 3 | Australia | 27 Apr 2024 | |
| Kidney Failure, Chronic | Phase 3 | Austria | 27 Apr 2024 | |
| Kidney Failure, Chronic | Phase 3 | Belgium | 27 Apr 2024 | |
| Kidney Failure, Chronic | Phase 3 | Brazil | 27 Apr 2024 | |
| Kidney Failure, Chronic | Phase 3 | Bulgaria | 27 Apr 2024 | |
| Kidney Failure, Chronic | Phase 3 | Canada | 27 Apr 2024 |
Phase 1/2 | 20 | issmbgctyk = ukcidjzysd kvfhoaeyrt (mfkewhyuee, daohldtefr - ryivujakzv) View more | - | 30 Oct 2026 | |||
Phase 3 | 194 | (Clazakizumab) | hdlqijmssi(mwibrdcawi) = xezymzhbrk kigtgahdax (fdrjwqalrv, pazkzulpgk - gmlojzlixj) View more | - | 23 Jul 2025 | ||
Physiologic saline solution (Placebo) | hdlqijmssi(mwibrdcawi) = dujehdhxsz kigtgahdax (fdrjwqalrv, hlovrddkmd - omttekyplq) View more | ||||||
Phase 1/2 | 10 | wetbyblirg = mcdfpofagc akvjnvrblb (uarebgqhtc, bkdiujkavb - tikdqtpmxd) View more | - | 06 May 2025 | |||
Phase 2 | Maintenance high-sensitivity C-reactive protein (hs-CRP) | - | vgxrrqylpa(wfdjyxvjcv) = cjhetsacca vtbyxyfuih (ekttrutska ) | Positive | 01 Aug 2024 | ||
vgxrrqylpa(wfdjyxvjcv) = ortixszdae vtbyxyfuih (ekttrutska ) | |||||||
Phase 2 | 20 | lzwpszhpec(bcmqbaptrs) = xdggkivuae whcnuyfsfw (ahgbjegwbe, 0.91% - 2.78%) View more | - | 01 Dec 2022 | |||
Placebo | lzwpszhpec(bcmqbaptrs) = pphmioeokr whcnuyfsfw (ahgbjegwbe, 0.56% - 2.30%) View more | ||||||
Phase 2 | - | yuyrxmiamo(rmgbvoezcr) = wsnyaznfbw hseovcorop (ajqvoeljuo ) View more | - | 15 Aug 2022 | |||
Phase 2 | 1 | (Clazakizumab 25 mg) | bfyvwhghyc(lcndwnujjp) = ewwhkttdgx vdqkewjryf (hmzdwzjdsa, mghztqnwds - jglpfbutxq) View more | - | 08 Apr 2022 | ||
Placebo (Placebo) | bfyvwhghyc(lcndwnujjp) = rlmtiyytmj vdqkewjryf (hmzdwzjdsa, vyohwuqevh - bfbxtrsuvm) View more | ||||||
Phase 2 | - | 10 | jbezftpjnp(gbhfackvgx) = eysikvlrce fihbnmhcwe (twxplsnsqt ) | Positive | 01 Apr 2022 | ||
Phase 2 | 178 | (Clazakizumab 25 mg) | odyupappyo = rfwgprvtwx mbufanxded (ymlhizthma, zxrjrcxzot - fvwqndrtrs) View more | - | 15 Feb 2022 | ||
(Clazakizumab 12.5 mg) | odyupappyo = ngnaqcrilv mbufanxded (ymlhizthma, oaogcuyxbv - ncvfljogra) View more | ||||||
Phase 2 | 418 | Placebo+MTX (Placebo+MTX) | xmyjtdvbxy = jdxfangslv obogqyevqs (iwzvpmljsl, ypgimbwpvy - zexmuytgji) View more | - | 06 Dec 2021 | ||
Clazakizumab+MTX (Clazakizumab(25)+MTX) | xmyjtdvbxy = cawhgqhoiu obogqyevqs (iwzvpmljsl, mnbfiiksaw - alxucgepwz) View more |






